Drug intelligence / Profile preview

NV-INF-1

Development stage: Preclinical
Lead developer: NanoViricides
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**NV-INF-1** is an investigational antiviral drug candidate developed by NanoViricides for the treatment of influenza. It is the injectable formulation (Injectable FluCide) within the FluCide program, designed to target influenza viruses through a novel nanoviricide platform that mimics viral entry mechanisms to bind and neutralize viruses. The company held a pre-IND meeting with the US FDA for NV-INF-1, indicating advancement toward clinical development for influenza infections.[8][16]

Other names: FluCide

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on NV-INF-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-INF-1.

Explore the full profile